VIABAHN BX Used in Fenestrated EVAR Study

Aortic Aneurysm, Abdominal Clinical Trial

Official title:

Heparin Bonded Balloon-expandable Stent Grafts for Branches of a Fenestrated Endovascular Aortic Repair Graft

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03310710
• Other study ID #: CAPCR 16-5084
• Status: Completed
• Phase: N/A
• Start date: February 13, 2017
• Est. completion date: November 1, 2019

Study information

• Verified date: November 2023
• Source: University Health Network, Toronto
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Fenestrated endovascular abdominal aortic aneurysm repair (FEVAR) is a procedure to treat abdominal aortic aneurysms which are not amenable to conventional repair or stenting. A stent is placed in the aorta and confines blood flow to a normal diameter lumen to remove pressure on the diseased aortic wall. Fenestrations (custom holes in the graft) are necessary to maintain blood flow to abdominal organs when the aneurysm sac extends to far proximally. These fenestrations are then typically aligned with their respective vessels using covered stents. These stents also help keep the arteries open.

Unfortunately some of the stents currently used occlude either immediately or over time, which can lead to organ failure, morbidity and death. A recent advancement in stent design has heparin bonded to the stent surface which prevents clot from forming. This new design has been shown to help maintain stent patency in other parts of the body. The investigators believe it may do the same for FEVAR patients. The proposed study is a 20-patient pilot to assess the safety of substituting a heparin bonded stent graft for FEVAR branches over a period of one year. Patients who are deemed eligible for FEVAR by a UHN multidisciplinary vascular conference will be recruited to the study. All the branches in their FEVAR will use the Viabahn BX stent in place of the current standard of care stent. They will then be followed per the standard of care for one year. Adverse events will be recorded and the rate of occlusion will be assessed based on CT imaging.

The investigators hypothesize that using heparin bonded stent grafts is safe and they will have a low rate of occlusion.

Description:

FEVAR branches can occlude jeopardizing perfusion of the organs they supply. A recent study has shown the rate of patency as 95.7% at 1 year and 88.6% at 4 years. Pooled analysis has shown a 4.5% rate of renal artery occlusion during 12 month follow up with 2.3% going on to dialysis and 1.4% requiring permanent dialysis. 1.8% of patients can go on to have mesenteric stenosis though these have been due to technical issues with the stents.

Studies have previously shown that the patency of vascular grafts can be improved by bonding heparin bonding to the surface of a graft material. For example in surgical bypass a Dacron graft bonded with heparin outperformed a conventional PTFE graft in terms of patency and clinical outcomes. Endovascular stent grafting with heparin bonded PTFE has also been shown to be superior to PTFE alone with a primary patency of 86.4% vs 79.9% in femoropopliteal disease. A recent trial has demonstrated impressive patency of 73% in long segment femoropopliteal disease (TASC C and D lesions) using a self expanding version of the heparin bonded, covered, Viabahn stent graft. Heparin bonded stent grafts have shown promise in preserving patency of other vessels. A pilot study demonstrating the safety of using the Viabahn Bx in FEVAR will support the rationale for larger studies of this question including randomization between conventional and heparin bonded stent grafts.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 20
• Est. completion date: November 1, 2019
• Est. primary completion date: October 17, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Fenestrated EVAR candidates as determined by the vascular interdisciplinary conference at UHN

Exclusion Criteria:

• Unable to provide informed consent (legally authorized representative is acceptable)

• Age < 18

• Patients with a known hypersensitivity to heparin, including those patients who have had a previous incidence of HIT (heparin induced thrombocytopenia) type II.

• Currently participating in another investigative clinical study

Related Conditions & MeSH terms

• Aneurysm
• Aortic Aneurysm
• Aortic Aneurysm, Abdominal

Intervention

Device:
• Viabahn BX stent
Viabahn BX stent graft used as the branch device with a fenestrated EVAR graft

Locations

Country	Name	City	State
Canada	University Health Network, Toronto General Hospital	Toronto	Ontario

Sponsors (1)

Lead Sponsor	Collaborator
University Health Network, Toronto

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Technical success related the Viabahn BX stent graft when used as the branch device with a fenestrated EVAR graft.	Successful deployment of the Viabahn BX stent graft without major adverse events, such as occlusion of the arteries, at the end of the fenestrated EVAR surgery.	Intraoperative (End of EVAR surgery)
Primary	Adverse event related to the Viabahn BX stent graft when used as the branch device with a fenestrated EVAR graft.	Any stent related adverse event, such as occlusion of the stent and stent fracture	12 months post surgery